MedTrace Logo

Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies

NCT00329329 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2012-03-23

No results posted yet for this study

Summary

The purpose of this study is to determine the maximally tolerated dose (MTD) and Phase 2 recommended dose of satraplatin when administered in combination with capecitabine in patients with advanced solid malignancies.

Conditions

Interventions

DRUG

satraplatin and capecitabine

satraplatin and capecitabine dose escalated per the dosing scheme

Sponsors & Collaborators

  • Agennix

    lead INDUSTRY

Principal Investigators

  • William Gradishar, MD · Northwestern University Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-01-31
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329329 on ClinicalTrials.gov